Celldex
Hampton, New Jersey, United States · Biotechnology, Health Care, Medical
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Hampton, New Jersey, United States
- Employees
- 190
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (CLDX)
- Website
- celldex.com
- Company page
Recent activity at Celldex
- : SEC 8-K (8.01): On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing the results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials of Barzolvolimab, which targets chronic spontaneous urticaria (CSU). This announcement is significant as it communicates the outcomes of important clinical trials that may impact the company's future product offerings and market strategy. The results could influence investor sentiment and the stock performance of Celldex, as they pertain to the efficacy and potential approval of a new treatment. The press release is attached as Exhibit 99.1.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On June 25, 2026, Celldex Therapeutics, Inc. conducted its 2026 Annual Meeting of Stockholders where significant corporate governance changes took place. Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the number of shares available for issuance under the plan by 3,400,000 shares, totaling 12,900,000. This amendment includes clarifications to tax withholding provisions on awards. Additionally, new directors were elected, with notable votes including Harry H. Penner, Jr. and Anthony S. Marucci, reflecting strong support with over 60 million votes for their re-election. The outcome of these proposals signifies strategic adjustments in the company's equity compensation approach and board composition, impacting future corporate governance and shareholder alignment.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
About Celldex: questions and answers
What does Celldex do?
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Where is Celldex headquartered?
Celldex is headquartered in Hampton, New Jersey, United States.
How many employees does Celldex have?
Celldex has about 190 employees.
What is the latest news on Celldex?
On Jun 26, 2026, SEC 8-K (8.01): On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing the results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials of Barzolvolimab, which targets chronic spontaneous urticaria (CSU). This announcement is significant as it communicates th
Is Celldex a public company?
Yes. Celldex is publicly traded under the ticker CLDX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy